Effect of antibiotics in the first week of life on faecal microbiota development

Emmy Van Daele 1, Kim Kamphorst 2,3, Arine M Vlieger 3, Gerben Hermes 1, Christian Milani 4,5, Marco Ventura 4,5, Clara Belzer 1, Hauke Smidt 6, Ruurd M van Elburg 6, Jan Knol 1,7

ABSTRACT

Background Infants are frequently exposed to antibiotics (AB) in the first week of life for suspected bacterial infections. Little is known about the effect of AB on the developing intestinal microbiota. Therefore, we studied intestinal microbiota development with and without AB exposure in the first week of life in term born infants.

Methods We analysed the faecal microbiota from birth until 2.5 years of age by 16s rRNA gene amplicon sequencing in a cohort with 56 term born infants, exposed to AB in the first week of life (AB+) (AB for 2–3 days (AB2, n=20), AB for 7 days (AB7, n=36)), compared with 126 healthy controls (AB-). The effects of AB and duration were examined in relation to delivery and feeding mode.

Results AB+ was associated with significantly increased relative abundance of Enterobacteriaceae at 3 weeks and 1 year and a decrease of Bifidobacteriaceae, from 1 week until 3 months of age only in vaginally delivered, but not in C-section born infants. Similar deviations were noted in AB7, but not in AB2. After AB, breastfed infants had lower relative abundance of potentially pathogenic Enterobacteriaceae compared with formula fed infants and recovered 2 weeks faster towards controls.

Conclusions AB exposure in the first week of life alters faecal microbiota development with deviations in the relative abundance of individual taxa until 1 year of age. These alterations can have long-term health consequences, which emphasises the need for future studies aiming at restoring intestinal microbiota after AB administration.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Up to 20% of neonates receive antibiotics because of (suspected) early-onset neonatal sepsis. In older infants, antibiotics have been shown to disturb the intestinal microbiota, but studies in newborns with a developing microbiota are limited.

⇒ Feeding type and delivery mode also affect the microbiota, but their effect in relation to antibiotic exposure in the first week of life has not yet been studied.

WHAT THIS STUDY ADDS

⇒ Antibiotic exposure in the first week of life affects microbiota development throughout the first year of life, with more profound deviations in infants born at term exposed for 7 days compared with only 2–3 days.

⇒ Antibiotic exposure in the first week of life resulted in deviations in the faecal microbiota development of vaginally delivered infants but not of C-section delivered infants compared with their respective controls. This could be attributed to the difference caused by delivery mode itself, with C-section delivered infants deviating from vaginal controls up to 1 month of age regardless of antibiotic exposure.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

⇒ This study underlines the importance of early cessation of antibiotics started at birth because of the prolonged effect on the intestinal microbiota and possible impact on health.

INTRODUCTION

During the first 1000 days of life, the intestinal microbiota impacts health in later life through the interdependent development of microbiota, immune system, growth and cognitive function.1,2 After birth, the intestinal microbiota develops rapidly, driven by exposure to microbes from maternal, environmental and dietary sources.3 During this early development, the intestinal microbiota is unstable and susceptible to perturbations such as those caused by antibiotic (AB) exposure. These perturbations may have long-term consequences on the developing microbiota and also on the developing immune system,4 growth5,6 and have already been associated with increased prevalence of asthma, allergies, coeliac disease, eczema, eosinophilic esophagitis, infantile colic, inflammatory bowel disease and obesity.7–11

In mice-based studies, AB exposure in the first week of life altered microbiota composition and immune function, but gavage with mature untreated microbiota, restored the perturbation and reduced the negative health effects.12 To understand the full impact in humans and develop restoration strategies, more knowledge is needed.

Worldwide, up to 20% of all neonates are prescribed ABs because of (suspected) early-onset neonatal sepsis, although in most cases, sepsis is unconfirmed and ABs could be discontinued after 48–72 hours.13–15 More prolonged AB exposure can gradually reduce overall diversity16 and richness17.
of the neonate’s intestinal ecosystem. Additionally, AB type also determines the microbial perturbation through specific mechanisms of action and host interactions. Studies in infants have been inconclusive, but indicated types with faster recovery towards the microbiota composition of controls. Therefore, more comparative studies are needed between durations and types in AB regimes to optimise AB administration. In this study, we investigated the microbiota development in a subset of the Intestinal Microbiota Composition after AB treatment in early life (INCA) cohort. The primary aim was to investigate the impact of AB exposure in the first days of life on microbiota development during the first 2.5 years of life. Secondary aims were to examine (1) short (2–3 days) versus long (7 days) AB administration, (2) different AB types and (3) the impact of feeding and delivery mode on AB perturbation.

MATERIALS AND METHODS

Study design

This prospective, observational study has been described previously. To study the impact of feeding mode on AB-induced deviations, we selected a subset of 182 infants with 1128 samples who were exclusively breast-fed (BF) or formula-fed (FF) in the first 3 months of life. An overview of collected samples and their selection for analyses reported here is provided in online supplemental figure 1). All AB+ infants received gentamicin, which was combined with penicillin (ABpen), amoxicillin (ABmix) or amoxicillin with clavulanic acid (ABAMC).

Data and faeces collection

Baseline characteristics were calculated using R 3.6.1 and statistical analysis of the baseline characteristics was performed using the Fisher exact test for the categorical variables and analysis of variance (ANOVA) for continuous variables. Not

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Baseline characteristics of the INCA cohort subset included in this study</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>AB-</td>
</tr>
<tr>
<td>GA, weeks (IQR)*</td>
<td>39.4 (38.5, 40.4)</td>
</tr>
<tr>
<td>Birth weight, mean grams (SD) *</td>
<td>3478 (515)</td>
</tr>
<tr>
<td>Birth weight for GA z-score (SD)</td>
<td>0.15 (1.2%)</td>
</tr>
<tr>
<td>Sex (Female %)</td>
<td>58 (46%)</td>
</tr>
<tr>
<td>Delivery mode (Vaginal %)</td>
<td>83 (66%)</td>
</tr>
<tr>
<td>Exclusive breast feeding at 3 m (Yes %)</td>
<td>47 (37%)</td>
</tr>
<tr>
<td>Additional AB 1–6 m (Yes %)*, **</td>
<td>10 (8.2%)</td>
</tr>
<tr>
<td>Additional AB 7–12 m (Yes %)</td>
<td>30 (27%)</td>
</tr>
</tbody>
</table>

Statistically significant differences are indicated with *p<0.05 compared with AB-, **p<0.05 compared with AB2.

AB+, infants who received AB during their first week of life. Birth weight for GA z-score is calculated according to the z-score formula. AB2: AB exposure for 2 to 3 days in the first week of life. AB7: AB exposure for 7 days. AB, antibiotics; AB-, control infants; GA, gestational age; m, months.
normally distributed variables were tested with the Kruskal-Wallis test and indicated by their median and IQR. Bonferroni correction was performed to correct for multiple testing.

Bioinformatic and statistical analysis of the sequence data
All analyses were performed in R 3.6.1.27 Samples were stratified into 11 age-based and right-closed intervals for statistical analysis (figure 1). The Jenks Natural Breaks Classification (classInt package) was used to calculate the optimal ranges.28 Because of increasing increments between sampling, the x-axis (age) was log2 transformed for visualisation.

Alpha diversity (within sample diversity) was calculated at ASV level using Picante30 and Microbiome31 packages and following metrics: Faith’s phylogenetic diversity,32 ASV richness, Shannon and Inverse Simpson. All except Shannon diversity needed logarithmic transformation to obtain normal distribution for one-way analysis of covariance. Consecutive analyses were corrected for the baseline characteristic that differed significantly between AB+ and AB- and between AB2 and AB7.

Temporal trends in relative abundance were visualised using local regression with locally estimated scatterplot smoothing using ggplot2. These relative abundances did not meet normality requirements and were therefore compared using beta regression with BetaReg33 per age interval. The effects of AB on the relative abundance of phyla were modelled including and excluding delivery mode, feeding mode and additional AB exposure between one and 6 months. The optimal beta regression models, based on Akaike and Bayesian information criteria, only required delivery mode, feeding mode and additional AB exposure during the first week of life, whereas UU uses presence or absence of ASVs. Pairwise UU and UW distance matrices were used to plot principle response curves (PRCs).36 PRC analysis is a redundancy analysis for interpreting longitudinal data. It visualises multivariate responses in a repeated observation design.56 37 The method was designed to analyse the treatment effect over time compared with controls, as it can disentangle the time-dependent effects from other possible determinants.38 59 In this study, time was displayed on the x-axis and the intestinal microbiota development was shown compared with AB- infants as the baseline reference group. Differences between AB groups were assessed per age interval using ANOVA in the vegan package.40

RESULTS
Baseline characteristics of INCA cohort subset
The baseline characteristics differed between AB- and AB+ for gestational age, birth weight and additional AB exposure between one to 6 months (table 1). Birth weight z-score (birth weight corrected for gestational age), however, was comparable. AB2 differed from AB7 with regard to additional AB exposure between 1 and 6 months (5% vs 34%, respectively, p=0.019). Baseline characteristics were comparable between the AB type groups (online supplemental table S1).

Antibiotic-induced alterations to intestinal microbiota development
AB exposure during the first week of life did not alter microbial alpha diversity between birth and 2.5 years (online supplemental figure 1). The temporal patterns of the four major phyla (95% of the average relative abundance) were compared with univariate analyses (figure 2). Relative abundance of Proteobacteria was high overall, during the first months of life. AB exposure further increased this relative abundance at 1 month (mean 43.6% AB+, 31.5% AB-) and 1 year (mean 17.6% AB+, 6.5% AB-). Actinobacteria peaked around 3 months, but AB exposure decreased their relative abundance at 1 week (mean 6.3% AB+, 18.2% AB-), 2 weeks (mean 8.4% AB+, 24.4% AB-), 1 month (mean 17.5% AB+, 27.2% AB-) and 3 months (mean 26.5% AB+, 34.4% AB-). The average relative abundance of Bacteroidetes was stable at approximately 10% during the first year of life. Firmicutes drastically increased in relative abundance towards 2.5 years. Both were unaffected by AB.

Effect of antibiotic duration on long-term microbiota development
Based on univariate statistics, the temporal trajectories of Actinobacteria and Proteobacteria were most affected by AB. Based on UU, ABs increased several members of the Enterobacteriaceae and decreased Bifidobacteriaceae at one and 2 weeks (online supplemental figure 2A). For WU, ABs impacted similar taxa at 1 year (p<0.05) (figure 3A). These AB deviations were similar in AB2 and AB7, but only the microbiota composition of AB7

Figure 2 Temporal trajectories of the relative abundance of the four main phyla in the developing intestinal microbiota from birth to 2.5 years of age. Thick lines represent the average with shading showing the 95% CI. Differences between AB+ and AB- were calculated using beta regression for each age category. * and vertical grey shading: difference in relative abundance (p<0.05), AB+, infants who received AB during their first week of life, AB-, infants who did not receive AB during their first week of life, LOESS, locally estimated scatterplot smoothing.

**Figure 3** WU-based PRC analysis is a special case of RDA for multivariate responses in a repeated observation design, which is applied here on the longitudinal infant intestinal microbiota dataset from birth till 2.5 years of age. (A) The infants who did not receive antibiotics during the first week of life (AB-), were compared as a baseline to the antibiotic exposed infants (AB+). Bacterial genera shown are the main drivers of the differences between AB+ and AB-: taxa on the same side of baseline as the curve are linked to an increased relative abundance at that time point, opposite sides indicate a decrease. (B) AB- was also compared as a baseline with the different antibiotic durations of 2–3 (AB2) or 7 days (AB7). Significance was tested at the different time points using an ANOVA like permutation test (*p<0.05 compared with baseline AB-). Covariates that were controlled for included additional AB exposure between the age of one and 6 months. AB+ infants who received AB during their first week of life; AB- infants who did not receive AB during their first week of life; AB2, AB exposure for 2–3 days in the first week of life indicated with light grey shading; AB7, AB exposure for 7 days indicated with grey shading; ANOVA, analysis of variance; ASV, amplicon sequence variants; PRC, principal response curve; RDA, redundancy analysis; WU, weighted UniFrac.

Impact of delivery and feeding mode on AB-associated deviations in the faecal microbiota development

Due to the relatively low number of faecal samples in the first week per feeding and delivery type (figure 1), effects were only reported in samples collected between 1 week and 2.5 years. Within AB-, microbiota deviated based on delivery mode from 1 week until 1 month (figure 4D). In vaginally delivered infants, the AB effect on the microbiota was still significant at 1 year with an increase of several Enterobacteriaceae, Enterococcaceae and Streptococcaceae and decrease in Bifidobacterium and Escherichia-Shigella. In contrast, no AB-mediated deviations were noted between C-section born infants.

Compared with AB- BF baseline, AB+ BF infants only deviated at 2 weeks, whereas AB+ FF infants showed longer deviations from the first week up to 1 month (figure 4A). Because there was also a feeding effect during the first 6 months, the AB effect was also analysed within the separate feeding groups. AB+ was associated with decreased *Bifidobacterium* relative abundance in FF (1 month) (figure 4C), which occurred later than in BF infants (2 weeks) (figure 4B). In turn, AB+ was associated with increased relative abundance of *Parabacteroides* in BF, and with increased relative abundance of *Enterobacteriaceae* and *Enterococcus* in FF infants.

**DISCUSSION**

In this prospective, observational INCA study, we examined the microbiota development after AB exposure during the first week of life and found perturbations in the faecal microbiota development from 1 week until 1 year of age. These perturbations included decreased relative abundance of *Bifidobacteriaceae* while potentially pathogenic *Enterobacteriaceae* increased. This study adds new insights into long-term compositional shifts after neonatal AB exposure. Our results corroborate findings in older infants with increased *Enterobacteriaceae* and decreased *Bifidobacteriaceae* after AB administration. Importantly, the severity and duration of AB-mediated microbiota perturbations increased with longer AB administration (5–7 vs 2–3 days). The results also align with a small study in preterm infants, where >5 days AB exposure intensified perturbations compared with 2–3 days.

*Bifidobacteriaceae* form a cornerstone in the early development of the immune system. They were shown to promote B-cell maturation and associations with decreased inflammatory responses and T-regulatory cell acquisition. *Enterobacteriaceae*, on the other hand, produce toxins and have lipopolysaccharides on their outer membranes, which causes inflammation.
Therefore, it is not surprising that reduced Bifidobacteriaceae, often combined with an increase in potentially pathogenic Enterobacteriaceae, like Shigella, Klebsiella and Enterobacter, have been associated with immune-mediated disorders like asthma.50 Similar deviations were also found in functional disorders like infantile colic51 and irritable bowel syndrome.52 The long-term microbiota effect of ABs and its associated negative health outcomes reinforce the need for implementing AB stewardship programs53–55 to avoid AB overuse.21 56 57 Delivery mode analyses were controlled for feeding mode and vice versa. AB-, infants who did not receive AB during their first week of life; AB+, infants who received AB during their first week of life also indicated within grey shading; ASV, amplicon sequence variants; BF, infants exclusively breast-fed in the first 3 months of life; FF, infants exclusively formula-fed in the first 3 months of life; PRC, principal response curve; Sectio, infants delivered through C-section, Vag, vaginally delivered infants; WU, weighted UniFrac.

Figure 4  WU-based PRC analyses in the different delivery and feeding mode groups. Bacterial genera shown are the main drivers for differences between the groups and the baseline: positive effect on the curve is linked to increased ASVs in the positive spectrum and decrease of those in the negative spectrum. (A) Breastfed controls (AB-BF) were compared as a baseline to antibiotic exposed (AB+) and FF infants. (B) Specifically featuring the AB effect in breastfed children, with breastfed control children as a baseline (AB-BF) and (C) formula-fed children, with formula-fed control children as a baseline (AB-). (D) Vaginally delivered control infants (AB-Vag) were compared as a baseline to antibiotic exposed (AB+) and C-section delivered (Sectio) infants. Significance was tested at the different time points using an ANOVA like permutation test (*p<0.05). Delivery mode analyses were controlled for feeding mode and vice versa.
coli, wheezing and food allergies in infants exposed for 5–7 days, but not for 2–3 days. It this observed difference between 2–3 days and 5–7 days exposure is the result of longer AB exposure or the result of a concomitant infection or inflammatory response is yet unclear. The AB7 infants were treated because of suspected early onset sepsis (EOS). EOS is rare in term infants, but it is difficult to distinguish from normal neonatal physiology after birth, and laboratory tests cannot always reliably detect or rule out EOS. Because the consequences of delaying treatment are significant, on average 82 newborns without EOS are treated for each case. In our study population, only two of the 36 AB infants had a positive blood culture. The others were also treated for 5–7 days because of elevated inflammatory markers or clinical symptoms. Uzan-Yulzari et al showed that the association between neonatal AB exposure and growth was independent of the neonatal infection state. This suggests that the differences in microbiota development after AB treatment in our study are more likely the result of the AB treatment duration itself than caused by a possible EOS. Our new findings emphasise the need for microbiota restoration to minimise aberrant immune development. Suggested strategies include prebiotics, probiotics and synbiotics but also faecal transfers, which partially restored the microbiota of mice exposed to AB for 7 days.

In vaginally delivered infants, the AB effect was most pronounced with microbiota deviations in the second week of life. C-section born infants, however, showed similar perturbations regardless of AB exposure. After C-section, microbiota perturbations occurred due to reduced vertical mother-infant transmission of important intestinal microbes such as Bacteroides and Bifidobacterium, while transmission of other microbes like skin and mouth bacteria increased, as well as due to maternal AB administration prior to cord clamping. C-section delivery already showed decreases in Bifidobacterium spp and increases in opportunistic pathogens from hospital environments like Enterobacter, Enterococcus and Klebsiella. This resembled the AB effect, which might explain the lack of an additional AB effect in C-section infants as these infants already lack the affected microbial groups from birth.

Feeding also has a major impact on early life microbiota development. In our study, ABs in the first week of life perturbed the microbiota of both BF and FF infants, but potentially pathogenic Enterobacteriaceae only increased in FF infants. Moreover, AB perturbations were still notable at 1 month in FF infants but only until 2 weeks in BF infants. Breastmilk probably aids restoration through components like human milk oligosaccharides and live bacteria, which stimulate the growth of bifidobacteria and reduce (potential) pathogens.

The strengths of this study are the quantity of samples and long-term follow-up. This enabled the investigation of the interplay of AB with delivery and feeding modes. Moreover, the quantity of sampling points allowed for detailed and long-term detection of AB-induced perturbations within individuals. This was relevant as AB impact was not uniform over time, suggesting that limited sampling points could lead to misinterpretation. Finally, the number of infants receiving additional courses of AB in the first year was low in this cohort, thereby reducing an important confounding factor.

The methodology for profiling the intestinal microbiota, which targeted the V3 hypervariable regions of the bacterial 16S rRNA gene, provides a cost-effective overview of bacterial community composition, however, resolution at species level is limited, and amplification bias cannot be unequivocally ruled out. The applied Probio_Uni and Probio_Rev primers were validated and, compared with other primers, they seemed to represent relevant members of the intestinal microbiota such as bifidobacteria more accurately, which makes them especially fit for analysing the intestinal microbiota of infants. For future research, whole genome shotgun sequencing could be used to increase the accuracy of species and strain detection. Another limitation may be that environmental factors and maternal-infant interactions could have been confounders, because AB+infants were admitted to neonatal wards, whereas AB-infants stayed with their mothers on the maternity ward and were discharged earlier. Last, we did not have sufficient data on perinatal AB exposure and were therefore unable to correct for it, although it is questionable to what extent this confounder is important to take into account. Additionally, the study was not primarily designed (and thus underpowered) to conclude on AB types. Nevertheless, our results suggest that AB7 induced less perturbations as it did not result in any differences from AB- (online supplemental figure 3B). The addition of the β-lactamase inhibitor clavulanic acid (AB7) was associated with higher levels of bifidobacteria compared with other AB types, which supports an earlier finding in a single subject. Dedicated studies are, however, needed to further elucidate the optimal regime with the least microbial perturbations.

In conclusion, AB exposure in the first week of life in term born infants disturbed the microbiota up to 1 year, with more significant deviations after longer AB exposure (5–7 days). Both C-section delivery and AB administration in the first week of life are associated with deviant intestinal microbiota, but the two combined are not associated with further deviation. Breastfeeding was associated with reduced severity and duration of perturbations compared with formula feeding. Our observations may help to elucidate why AB-exposed infants have more health problems. It may also support the development of preventive and curative strategies after AB exposure to stimulate the growth of beneficial microbiota in order to prevent future health problems.

Author affiliations
1 Laboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands
2 Pediatrics, Amsterdam Gastroenterology, Metabolism & Nutrition, Amsterdam Reproduction & Development, Amsterdam UMC Locate AMC, Amsterdam, The Netherlands
3 Pediatrics, St. Antonius Hospital, Nieuwegein, The Netherlands
4 Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma Department of Chemical Life Sciences and Environmental Sustainability, Parma, Emilia-Romagna, Italy
5 Interdepartmental Research Centre "Microbiome Research Hub", University of Parma, Parma, Emilia-Romagna, Italy
6 Pediatrics, Amsterdam Gastroenterology, Metabolism & Nutrition, Amsterdam Reproduction & Development Amsterdam, Amsterdam UMC Locate AMC, Amsterdam, North Holland, The Netherlands
7 Nutricia Research BV, Utrecht, The Netherlands

Acknowledgements First of all, we want to thank the mothers and infants who participated in the INCA cohort for their time and effort. Second, we would like to acknowledge the help of all the hospital staff in the recruitment and collection of data, and especially Carin Bunkers and Nicole Rutten for their support. Last, we thank Marta MagniBlock and GeroProbi srl (Parma, Italy) for performing the DNA extraction and sequencing of the faecal samples.

Contributors JK and RMvE contributed equally to this paper. EVD conceptualized the research questions, wrote the manuscript, performed the analyses and data interpretation, wrote and revised the manuscript. KK provided data and revised the manuscript. AMV performed the manuscript. BH conceptualized the original cohort study and provided a clinical outlook for data interpretation and writing and revised the manuscript. GH conceptualized the research questions, provided support for the data analysis and revised the manuscript. CM performed data analysis and revised the manuscript. MV performed data analysis and revised the manuscript. CB acquired funding and revised the manuscript. HS supervised the research activity and revised the manuscript. RMvE conceptualised the original cohort study and provided a clinical outlook for data interpretation and writing and

F6 Van Daele E, et al. Arch Dis Child Fetal Neonatal Ed 2022;0:F1–F8. doi:10.1136/archdischild-2021-322861

Copyright.
The microbiome in early life: implications for health and disease. New insights from the first 1000 days of life and beyond.


Yoshida K. Tableone: Create Table 1 to Describe Baseline Characteristics. R package version 0.11.1, 2020. Available: https://cran.r-project.org/package=tableone


van Daele E, et al. Arch Dis Child Fetal Neonatal Ed 2022;0:F1–F8. doi:10.1136/archdischild-2021-322861

F7
Original research


71 Rintala A, Pietilä S, Mumukka E, et al. Gut microbiota analysis results are highly dependent on the 16S rRNA gene target region, whereas the impact of DNA extraction is minor. *J Biomol Tech* 2017:28:19.


## Supplementary Table 1

<table>
<thead>
<tr>
<th></th>
<th>AB-</th>
<th>AB\textsuperscript{PEN}</th>
<th>AB\textsuperscript{AMX}</th>
<th>AB\textsuperscript{AMC}</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n</strong></td>
<td>126</td>
<td>33</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td><strong>Gestational age (GA), weeks [IQR]</strong></td>
<td>39.4 [38.5,40.4]</td>
<td>40.5 [39.3,41.1]</td>
<td>40.1 [39.4,40.5]</td>
<td>40.5 [40.2,41.3]</td>
</tr>
<tr>
<td><strong>Birth weight, mean grams (SD)</strong></td>
<td>3478 (515)</td>
<td>3733 (540)</td>
<td>3528 (326)</td>
<td>3797 (422)</td>
</tr>
<tr>
<td><strong>Birth weight for GA z-score (SD)</strong></td>
<td>0.2 (1.2%)</td>
<td>0.5 (1%)</td>
<td>0.1 (1%)</td>
<td>0.4 (1%)</td>
</tr>
<tr>
<td><strong>Sex (Female %)</strong></td>
<td>58 (46%)</td>
<td>16 (49%)</td>
<td>7 (70%)</td>
<td>5 (39%)</td>
</tr>
<tr>
<td><strong>Delivery mode (Vaginal %)</strong></td>
<td>83 (66%)</td>
<td>24 (73%)</td>
<td>7 (70%)</td>
<td>10 (77%)</td>
</tr>
<tr>
<td><strong>Exclusive breastfeeding at 3m (Yes %)</strong></td>
<td>47 (37%)</td>
<td>12 (36%)</td>
<td>7 (70%)</td>
<td>4 (31%)</td>
</tr>
<tr>
<td><strong>Additional AB 1-6m (Yes %)</strong></td>
<td>10 (8.2%)</td>
<td>9 (28%)</td>
<td>1 (10%)</td>
<td>3 (23%)</td>
</tr>
<tr>
<td><strong>Additional AB 7-12m (Yes %)</strong></td>
<td>30 (27%)</td>
<td>5 (17%)</td>
<td>0 (0%)</td>
<td>4 (36%)</td>
</tr>
</tbody>
</table>

**Supplementary Table S1.** Baseline characteristics of the INCA cohort subset included in this study, grouped per antibiotic type.

There were no statistical differences between these groups for the listed variables. Birth weight for GA z-score is calculated according to the z-score formula \(^1\) AB: antibiotics, AB\textsuperscript{-}: control infants, AB\textsuperscript{PEN}: antibiotic exposure in first week of life with gentamicin and penicillin, AB\textsuperscript{AMX}: gentamicin and amoxicillin, AB\textsuperscript{AMC}: gentamicin with amoxicillin and clavulanic acid, GA: gestational age, IQR: not normally distributed variables are indicated by their median and inter quartile range [IQR], m: months, SD: standard deviation, There were no statistically significant differences with p-values < 0.05 for AB\textsuperscript{+} compared to AB\textsuperscript{-} or for AB\textsuperscript{7} compared to AB\textsuperscript{2}.
**Supplementary Figure 1.** Alpha diversity in age categories from birth to 2.5 years of age. Alpha diversity at different age categories of the antibiotic (AB+) exposed and non-AB infants (AB-) did not differ at any of the time points, using one-way Analysis of Covariance (ANCOVA) corrected for additional AB exposure between one and six months of age, ASV: Amplicon sequence variants.
**Supplementary Figure 2**

(a) Antibiotic effect

Unweighted UniFrac (UU)-based Principal Response Curves (PRC) complementary to the PRC in Figure 3. The infants who did not receive antibiotics during the first week of life (AB-), were compared as a baseline to the antibiotic exposed infants (AB+). Bacterial genera shown are the main drivers of the differences between AB+ and AB-: taxa on the same side of baseline as the curve are linked to an increased relative abundance at that time point, opposite sides indicate a decrease.

(b) Duration effect

AB- was also compared as a baseline with the different antibiotic durations of 2 to 3 (AB2) or 7 days (AB7).

Significance was tested at the different time points using an ANOVA like permutation test (* = p-value < 0.05 compared to baseline AB-). Covariates that were controlled for included additional AB exposure between the age of one and six months. AB-: infants who did not receive AB during their first week of life, AB+: infants who received AB during their first week of life also indicated within grey shading, AB2: AB exposure for 2 to 3 days in the first week of life, AB7: AB exposure for 7 days in the first week of life, ASV: Amplicon sequence variants, UU: unweighted UniFrac.
Supplementary Figure 3

Supplementary Figure 3. Weighted (WU) (a) and Unweighted UniFrac (UU) (b) -based Principal Response Curves (PRC) comparing the impact of different antibiotic types administered during the first week of life. The infants who did not receive antibiotics during the first week of life (AB-), were compared as a baseline to the different types of antibiotics AB\textsuperscript{PEN}, AB\textsuperscript{AMX} and AB\textsuperscript{AMC}.

Significance was tested at the different time points using an ANOVA like permutation test (* = p-value < 0.05 compared to baseline AB-). AB: infants who did not receive AB during their first week of life, AB\textsuperscript{PEN}: antibiotic exposure in first week of life with gentamicin and penicillin, AB\textsuperscript{AMX}: gentamicin and amoxicillin, AB\textsuperscript{AMC}: gentamicin with amoxicillin and clavulanic acid. ASV: Amplicon sequence variants, UU: unweighted UniFrac, WU: weighted UniFrac.
Supplementary file 1 – material and methods

Study design summary

In short, 436 infants born at term were recruited from maternity and neonatal wards of four teaching hospitals in the Netherlands. Infants with suspicion of infection, who received a combination of broad-spectrum ABs in their first week of life (AB+), and healthy, unexposed controls (AB-) were included. Blood cultures were taken before AB exposure was started. In case of a negative blood culture, combined with a low clinical suspicion of infection and low C-reactive protein, ABs were discontinued after 2 to 3 days (AB2). Otherwise ABs were continued for 5 to usually 7 days (AB7). Infants without sufficient follow up, less than 7 samples over the first three years of age, were not included for this study.

Detailed material and methods:

Partial 16S rRNA gene amplicons were generated by using two consecutive PCR reactions. First, the V3 region of the 16S rRNA gene was amplified using primers (Probio_Uni/Probio_Rev) with adapters overhanging at the 5’ end. Thermal cycling conditions were as follows: 5 min at 95°C; 35 cycles of 30 s at 94°C, 30 s at 55°C and 90 s at 72°C; followed by 10 min at 72°C. The PCR amplicons, which were validated and checked on size by electrophoresis on a 2200 Tape Station instrument (Agilent Technologies, USA), were cleaned by magnetic Agencourt AMPure XP DNA purification beads (Beckman Coulter Genomics GmbH). To enable multiplexing, unique combinations of Tag barcodes (8 base pairs) were attached using a second PCR with the following cycling conditions: 3 min at 95 °C; 8 cycles of 30 s at 95°C, 30 s at 55°C and 30 s at 72°C; followed by 5 min at 72°C. Each PCR was performed with a Verity Thermocycler (Applied Biosystems, USA). DNA obtained was purified by means of a magnetic purification step involving Agencourt AMPure XP DNA purification beads (Beckman Coulter Genomics GmbH, Bernried, Germany). The DNA concentration of the amplified sequence library was determined by a fluorometric Qubit quantification system (Life Technologies, USA). Amplicons were diluted to a concentration of 4 nM in 10-μl quantities and combined to prepare the pooled final library. 16S rRNA gene amplicon sequencing was performed using an Illumina MiSeq sequencer and MiSeq Reagent Kit v3 chemicals (Illumina Inc., USA) at GenProbio srl (Parma, Italy) according to manufacturer’s instructions.